Abstract
NSAIDs represent one of the most commonly used therapeutic drug groups worldwide. 1.5percent of the world population is estimated as taking NSAIDs. However, their use is not risk free and gastrointestinal (GI) lesions do appear, which is indeed the main reason for their toxicity. Frequently (50percent) NSAID-induced GI-Lesions are asymptomatic, 71percent of GI perforations and 50percent of upper gastric hemorrhages (UGH) are associated with taking NSAIDs How frequent GI lesions appear is directly related to whether the patient is in a risk group or not. Factors increasing the risk of GI lesions occurring are the following: being older than 60, using corticoids or other NSAIDs concomitantly, having a history of duodenal ulcer, alcohol consumption, smoking or taking oral anticoagulants. As the toxicity and how frequent the lesions appear depend on which drug is used, there is a need for research into new drugs which are both clinically effective and safer to use. GI toxicity of NSAIDs is mediated by two mechanisms, direct toxicity and prostaglandin synthesis inhibition or sistemic mechanism. Due to the relatively recent discoveries concerning the physiopathology of inflammation and gastric physiology, research into new NSAID derivatives is taking place. Such derivatives are prodrugs, galenic buffer forms, selective COX-2 inhibitors, isomeric compounds, NO-donors, and as a future possibility, phosphodiesterase inhibitors.
Keywords: Antiinflamatory Agents Less, Gastrointestinal Tract, COX-2 inhibitors, cyclooxygenase-2 COX-2, Polymorphouuclear leukocyte, PMN-endothelial cell, Intercellular adhesion molecular 1 ICAM, Water immersion restraint WIR, Oxidative Metabolism
Current Pharmaceutical Design
Title: Antiinflamatory Agents Less Dangerous for Gastrointestinal Tract
Volume: 7 Issue: 10
Author(s): M. Rodriguez-Tellez, F. Arguelles, J. M. Herrerias, Jr., D. Ledro, J. Esteban and J. M. Herrerias
Affiliation:
Keywords: Antiinflamatory Agents Less, Gastrointestinal Tract, COX-2 inhibitors, cyclooxygenase-2 COX-2, Polymorphouuclear leukocyte, PMN-endothelial cell, Intercellular adhesion molecular 1 ICAM, Water immersion restraint WIR, Oxidative Metabolism
Abstract: NSAIDs represent one of the most commonly used therapeutic drug groups worldwide. 1.5percent of the world population is estimated as taking NSAIDs. However, their use is not risk free and gastrointestinal (GI) lesions do appear, which is indeed the main reason for their toxicity. Frequently (50percent) NSAID-induced GI-Lesions are asymptomatic, 71percent of GI perforations and 50percent of upper gastric hemorrhages (UGH) are associated with taking NSAIDs How frequent GI lesions appear is directly related to whether the patient is in a risk group or not. Factors increasing the risk of GI lesions occurring are the following: being older than 60, using corticoids or other NSAIDs concomitantly, having a history of duodenal ulcer, alcohol consumption, smoking or taking oral anticoagulants. As the toxicity and how frequent the lesions appear depend on which drug is used, there is a need for research into new drugs which are both clinically effective and safer to use. GI toxicity of NSAIDs is mediated by two mechanisms, direct toxicity and prostaglandin synthesis inhibition or sistemic mechanism. Due to the relatively recent discoveries concerning the physiopathology of inflammation and gastric physiology, research into new NSAID derivatives is taking place. Such derivatives are prodrugs, galenic buffer forms, selective COX-2 inhibitors, isomeric compounds, NO-donors, and as a future possibility, phosphodiesterase inhibitors.
Export Options
About this article
Cite this article as:
Rodriguez-Tellez M., Arguelles F., Herrerias, Jr. M. J., Ledro D., Esteban J. and Herrerias M. J., Antiinflamatory Agents Less Dangerous for Gastrointestinal Tract, Current Pharmaceutical Design 2001; 7 (10) . https://dx.doi.org/10.2174/1381612013397663
DOI https://dx.doi.org/10.2174/1381612013397663 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Recent Patents on Development of Nucleic Acid-based Antiviral Drugs against Seasonal and Pandemic Influenza Virus Infections
Recent Patents on Anti-Infective Drug Discovery Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Vitamin D in COPD - A Pleiotropic Micronutrient in a Multisystem Disease
Current Respiratory Medicine Reviews SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Inflammatory Modulation of Hepatocyte Apoptosis by Nitric Oxide: In Vivo, In Vitro, and In Silico Studies
Current Molecular Medicine Injectable Liposomal Formulations: Systematic Analysis for Regulatory Purposes
Pharmaceutical Nanotechnology Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry An In-Silico Investigation of Phytochemicals as Antiviral Agents Against Dengue Fever
Combinatorial Chemistry & High Throughput Screening Synthesis of (±) Travoprost and its Analogs
Letters in Organic Chemistry Structure-Guided Design of Antibodies
Current Computer-Aided Drug Design Preface [Hot Topic: Chemokines (Guest Editor: Chang H. Kim)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Wolbachia and Its Implications for the Immunopathology of Filariasis
Endocrine, Metabolic & Immune Disorders - Drug Targets Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Editorial A New Year of Excellence
Current Molecular Medicine